We are analyzing https://link.springer.com/article/10.1007/s00262-011-1158-4.

Title:
Regulatory T cells increase in breast cancer and in stage IV breast cancer | Cancer Immunology, Immunotherapy
Description:
Expression levels of VEGF and Her-2, levels of T-regulatory (Treg) cells, levels of CD3+ cells, and ratios of Th (CD4+ T cells)/Tr (Treg) cells were compared between stage I, II, III, and IV breast cancer patients (n = 120) prior to chemotherapy and healthy women (n = 30). Cells from peripheral blood were counted by flow cytometry, Her-2 and VEGF expression was detected by pathological examination, and Her-2 was detected by FISH. Breast cancer patients had more Treg cells and a lower ratio of Th/Tr cells than the healthy women. Stage IV breast cancer patients had more Treg cells and a lower ratio of Th/Tr cells than stage I, II, or III breast cancer patients. Patients positive for VEGF had a lower ratio of Th/Tr cells compared with patients negative for VEGF, and those positive for both VEGF and Her-2 also had a lower ratio of Th/Tr cells compared with patients not positive for both VEGF and Her-2. The decreased Th/Tr cells ratio indicates impaired immune function, suggesting that the stage IV breast cancer and the Her-2/VEGF-positive breast cancer patients have lower immune function.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Science
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,642,828 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't tell how the site generates income.

While many websites aim to make money, others are created to share knowledge or showcase creativity. People build websites for various reasons. This could be one of them. Link.springer.com could have a money-making trick up its sleeve, but it's undetectable for now.

Keywords {🔍}

cancer, google, scholar, article, breast, cells, pubmed, cas, patients, regulatory, vegf, stage, ratio, clin, growth, factor, immunotherapy, yang, expression, lower, thtr, access, res, privacy, cookies, content, liu, levels, treg, immune, cell, endothelial, oncol, publish, search, wang, peripheral, immunol, med, xue, vascular, springer, anticancer, function, data, information, log, journal, research, november,

Topics {✒️}

t-helper/t-regulator lymphocyte ratio month download article/chapter shun-chang jiao node-negative breast carcinoma article cancer immunology liang-liang wu foxp3+ regulatory t-cells related subjects full article pdf invasive breast cancer cd4+ cd25+ foxp3+ privacy choices/manage cookies anticancer immune status breast cancer patients rankl-rank signalling primary breast tumors cell infiltrates varies clinical oncology/college regulatory t-cells article wang european economic area zacarías fluck mf dynamic cross-talk erb-b2 amplification predicts reduced survival conditions privacy policy tumour-infiltrating regulatory c-erbb-2 expression impaired immune function van duivenvoorde lm accepting optional cookies breast cancer /tr cells ratio jun-lan yang clinical significance p53-independent mechanism conejo-garcia jr lower immune function author information authors check access effect prediction markers chang km article log instant access /tr cells compared journal finder publish t-regulatory tumor-infiltrating lymphocytes xue patients negative

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Regulatory T cells increase in breast cancer and in stage IV breast cancer
         description:Expression levels of VEGF and Her-2, levels of T-regulatory (Treg) cells, levels of CD3+ cells, and ratios of Th (CD4+ T cells)/Tr (Treg) cells were compared between stage I, II, III, and IV breast cancer patients (n = 120) prior to chemotherapy and healthy women (n = 30). Cells from peripheral blood were counted by flow cytometry, Her-2 and VEGF expression was detected by pathological examination, and Her-2 was detected by FISH. Breast cancer patients had more Treg cells and a lower ratio of Th/Tr cells than the healthy women. Stage IV breast cancer patients had more Treg cells and a lower ratio of Th/Tr cells than stage I, II, or III breast cancer patients. Patients positive for VEGF had a lower ratio of Th/Tr cells compared with patients negative for VEGF, and those positive for both VEGF and Her-2 also had a lower ratio of Th/Tr cells compared with patients not positive for both VEGF and Her-2. The decreased Th/Tr cells ratio indicates impaired immune function, suggesting that the stage IV breast cancer and the Her-2/VEGF-positive breast cancer patients have lower immune function.
         datePublished:2011-11-25T00:00:00Z
         dateModified:2011-11-25T00:00:00Z
         pageStart:911
         pageEnd:916
         sameAs:https://doi.org/10.1007/s00262-011-1158-4
         keywords:
            Breast cancer
            Her-2
            VEGF
            Treg cells
            Th/Tr cells ratio
            Oncology
            Immunology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-011-1158-4/MediaObjects/262_2011_1158_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-011-1158-4/MediaObjects/262_2011_1158_Fig2_HTML.jpg
         isPartOf:
            name:Cancer Immunology, Immunotherapy
            issn:
               1432-0851
               0340-7004
            volumeNumber:61
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Zhi-kuan Wang
               affiliation:
                     name:Chinese PLA General Hospital
                     address:
                        name:Cancer Center, Chinese PLA General Hospital, Beijing, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Bo Yang
               affiliation:
                     name:Chinese PLA General Hospital
                     address:
                        name:Cancer Center, Chinese PLA General Hospital, Beijing, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Hui Liu
               affiliation:
                     name:Chinese PLA General Hospital
                     address:
                        name:Cancer Center, Chinese PLA General Hospital, Beijing, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Yi Hu
               affiliation:
                     name:Chinese PLA General Hospital
                     address:
                        name:Cancer Center, Chinese PLA General Hospital, Beijing, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jun-lan Yang
               affiliation:
                     name:Chinese PLA General Hospital
                     address:
                        name:Cancer Center, Chinese PLA General Hospital, Beijing, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Liang-liang Wu
               affiliation:
                     name:Chinese PLA General Hospital
                     address:
                        name:Cancer Center, Chinese PLA General Hospital, Beijing, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Zhen-hong Zhou
               affiliation:
                     name:Chinese PLA General Hospital
                     address:
                        name:Department of Pathology, Chinese PLA General Hospital, Beijing, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Shun-chang Jiao
               affiliation:
                     name:Chinese PLA General Hospital
                     address:
                        name:Cancer Center, Chinese PLA General Hospital, Beijing, China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Regulatory T cells increase in breast cancer and in stage IV breast cancer
      description:Expression levels of VEGF and Her-2, levels of T-regulatory (Treg) cells, levels of CD3+ cells, and ratios of Th (CD4+ T cells)/Tr (Treg) cells were compared between stage I, II, III, and IV breast cancer patients (n = 120) prior to chemotherapy and healthy women (n = 30). Cells from peripheral blood were counted by flow cytometry, Her-2 and VEGF expression was detected by pathological examination, and Her-2 was detected by FISH. Breast cancer patients had more Treg cells and a lower ratio of Th/Tr cells than the healthy women. Stage IV breast cancer patients had more Treg cells and a lower ratio of Th/Tr cells than stage I, II, or III breast cancer patients. Patients positive for VEGF had a lower ratio of Th/Tr cells compared with patients negative for VEGF, and those positive for both VEGF and Her-2 also had a lower ratio of Th/Tr cells compared with patients not positive for both VEGF and Her-2. The decreased Th/Tr cells ratio indicates impaired immune function, suggesting that the stage IV breast cancer and the Her-2/VEGF-positive breast cancer patients have lower immune function.
      datePublished:2011-11-25T00:00:00Z
      dateModified:2011-11-25T00:00:00Z
      pageStart:911
      pageEnd:916
      sameAs:https://doi.org/10.1007/s00262-011-1158-4
      keywords:
         Breast cancer
         Her-2
         VEGF
         Treg cells
         Th/Tr cells ratio
         Oncology
         Immunology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-011-1158-4/MediaObjects/262_2011_1158_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-011-1158-4/MediaObjects/262_2011_1158_Fig2_HTML.jpg
      isPartOf:
         name:Cancer Immunology, Immunotherapy
         issn:
            1432-0851
            0340-7004
         volumeNumber:61
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Zhi-kuan Wang
            affiliation:
                  name:Chinese PLA General Hospital
                  address:
                     name:Cancer Center, Chinese PLA General Hospital, Beijing, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Bo Yang
            affiliation:
                  name:Chinese PLA General Hospital
                  address:
                     name:Cancer Center, Chinese PLA General Hospital, Beijing, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Hui Liu
            affiliation:
                  name:Chinese PLA General Hospital
                  address:
                     name:Cancer Center, Chinese PLA General Hospital, Beijing, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Yi Hu
            affiliation:
                  name:Chinese PLA General Hospital
                  address:
                     name:Cancer Center, Chinese PLA General Hospital, Beijing, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jun-lan Yang
            affiliation:
                  name:Chinese PLA General Hospital
                  address:
                     name:Cancer Center, Chinese PLA General Hospital, Beijing, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Liang-liang Wu
            affiliation:
                  name:Chinese PLA General Hospital
                  address:
                     name:Cancer Center, Chinese PLA General Hospital, Beijing, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Zhen-hong Zhou
            affiliation:
                  name:Chinese PLA General Hospital
                  address:
                     name:Department of Pathology, Chinese PLA General Hospital, Beijing, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Shun-chang Jiao
            affiliation:
                  name:Chinese PLA General Hospital
                  address:
                     name:Cancer Center, Chinese PLA General Hospital, Beijing, China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Immunology, Immunotherapy
      issn:
         1432-0851
         0340-7004
      volumeNumber:61
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Chinese PLA General Hospital
      address:
         name:Cancer Center, Chinese PLA General Hospital, Beijing, China
         type:PostalAddress
      name:Chinese PLA General Hospital
      address:
         name:Cancer Center, Chinese PLA General Hospital, Beijing, China
         type:PostalAddress
      name:Chinese PLA General Hospital
      address:
         name:Cancer Center, Chinese PLA General Hospital, Beijing, China
         type:PostalAddress
      name:Chinese PLA General Hospital
      address:
         name:Cancer Center, Chinese PLA General Hospital, Beijing, China
         type:PostalAddress
      name:Chinese PLA General Hospital
      address:
         name:Cancer Center, Chinese PLA General Hospital, Beijing, China
         type:PostalAddress
      name:Chinese PLA General Hospital
      address:
         name:Cancer Center, Chinese PLA General Hospital, Beijing, China
         type:PostalAddress
      name:Chinese PLA General Hospital
      address:
         name:Department of Pathology, Chinese PLA General Hospital, Beijing, China
         type:PostalAddress
      name:Chinese PLA General Hospital
      address:
         name:Cancer Center, Chinese PLA General Hospital, Beijing, China
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Zhi-kuan Wang
      affiliation:
            name:Chinese PLA General Hospital
            address:
               name:Cancer Center, Chinese PLA General Hospital, Beijing, China
               type:PostalAddress
            type:Organization
      name:Bo Yang
      affiliation:
            name:Chinese PLA General Hospital
            address:
               name:Cancer Center, Chinese PLA General Hospital, Beijing, China
               type:PostalAddress
            type:Organization
      name:Hui Liu
      affiliation:
            name:Chinese PLA General Hospital
            address:
               name:Cancer Center, Chinese PLA General Hospital, Beijing, China
               type:PostalAddress
            type:Organization
      name:Yi Hu
      affiliation:
            name:Chinese PLA General Hospital
            address:
               name:Cancer Center, Chinese PLA General Hospital, Beijing, China
               type:PostalAddress
            type:Organization
      name:Jun-lan Yang
      affiliation:
            name:Chinese PLA General Hospital
            address:
               name:Cancer Center, Chinese PLA General Hospital, Beijing, China
               type:PostalAddress
            type:Organization
      name:Liang-liang Wu
      affiliation:
            name:Chinese PLA General Hospital
            address:
               name:Cancer Center, Chinese PLA General Hospital, Beijing, China
               type:PostalAddress
            type:Organization
      name:Zhen-hong Zhou
      affiliation:
            name:Chinese PLA General Hospital
            address:
               name:Department of Pathology, Chinese PLA General Hospital, Beijing, China
               type:PostalAddress
            type:Organization
      name:Shun-chang Jiao
      affiliation:
            name:Chinese PLA General Hospital
            address:
               name:Cancer Center, Chinese PLA General Hospital, Beijing, China
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Cancer Center, Chinese PLA General Hospital, Beijing, China
      name:Cancer Center, Chinese PLA General Hospital, Beijing, China
      name:Cancer Center, Chinese PLA General Hospital, Beijing, China
      name:Cancer Center, Chinese PLA General Hospital, Beijing, China
      name:Cancer Center, Chinese PLA General Hospital, Beijing, China
      name:Cancer Center, Chinese PLA General Hospital, Beijing, China
      name:Department of Pathology, Chinese PLA General Hospital, Beijing, China
      name:Cancer Center, Chinese PLA General Hospital, Beijing, China
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(110)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

3.76s.

LINK . SPRINGER . COM {}